Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trialAna Oaknin, Juan Cueva, Laurence Gladieff et al.|The Lancet|2023Cited by 225
Heterogeneous treatment effects of adjuvant therapy for patients with cervical cancer in the intermediate‐risk groupAyumi Taguchi, Munetaka Takekuma, Y. Nakajima et al.|Cancer Medicine|2023Cited by 10